US Patent Issued to NANJING RUIJIE PHARMA on March 17 for "Substituted [1,2,4triazolo[1,5-apyrazines as spleen tyrosine kinase inhibitors" (Chinese Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,577,248, issued on March 17, was assigned to NANJING RUIJIE PHARMA Co. LTD. (Nanjing, China).

"Substituted [1,2,4triazolo[1,5-apyrazines as spleen tyrosine kinase inhibitors" was invented by Junbo Zhang (Nanjing, China), Shuhao Zhu (Nanjing, China) and Xiaoxin Qi (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides compounds of Formula (I) which can be used as Syk inhibitors and potently as therapeutic agents against diseases mediated by Syk."

The patent was filed on May 28, 2021, under Application No. 17/928,616.

*For further information, including images, charts and tables, please visit: http://patft.uspto.g...